About Gilead Sciences
Gilead Sciences benefits and support
Gilead Sciences news and updates
Gilead partners with ViiV Healthcare group
Gilead has reached an agreement with patent holder ViiV Healthcare on a licence for its HIV blockbuster drug Biktarvy, ending a global patent dispute.
Jan 1, 2022 | juve-patent.comGilead Sciences, Inc. files suit against Safe Chain Solutions
Gilead filed the original federal complaint against Safe Chain and the Boyd brothers on July 22, 2021, and filed two amended complaints on Aug. 19, 2021 and Oct. 14, 2021.
Jan 1, 2022 | stardem.comCincinnati invests into Gilead Sciences, Inc.
The Ohio-based Cincinnati Company has invested 0.62% in Gilead Sciences, Inc. (NASDAQ:GILD).
Jan 1, 2019 | altcoinmercury.comMorgan Stanley invests into Gilead Sciences, Inc.
Morgan Stanley has invested 0.1% in Gilead Sciences, Inc. (NASDAQ:GILD).
Jan 1, 2019 | investtribune.comGilead Sciences, Inc. invests into Hookipa Pharma Inc. in $59.6M
Biotech: Gilead Sciences (NASDAQ: GILD ) was a strategic investor in a $59.6M Series C round in Hookipa Biotech.
Jan 1, 2017 | seekingalpha.comChoate Investment Advisors LLC invests into Gilead Sciences, Inc.
Choate Investment Advisors has invested 0.04% in Gilead Sciences, Inc. (NASDAQ:GILD).
Jan 1, 2019 | enbulletin.comDiversified Financial, Inc. invests into Gilead Sciences, Inc.
Diversified Company has invested 0.08% in Gilead Sciences, Inc. (NASDAQ:GILD).
Jan 1, 2019 | investtribune.comPlaybill partners with Gilead Sciences, Inc.
This year, Playbill is partnering with Gilead to bring the event back with plans to “up the experience” by making it into a live and virtual hybrid event held at Sony Hall on Sunday, November 21.
Jan 1, 2021 | yahoo.comGilead Sciences, Inc. partnered with Elton John AIDS Foundation on Sep 9th 19'.
Gilead Sciences and the Elton John AIDS Foundation have announced the launch of an initiative designed to reduce new HIV infections and deaths from AIDS-related illnesses in Eastern Europe and Central Asia (EECA).
Jan 1, 2019 | philanthropynewsdigest.orgHookipa Pharma Inc. partnered with Gilead Sciences, Inc. on Jan 6th 20'.
In June 2018, Hookipa Pharma entered a collaboration and licensing agreement with Gilead Sciences, to develop therapies targeting HIV and HBV (hepatitis B).
Jan 1, 2020 | marketrealist.comNurix Therapeutics, Inc. partnered with Gilead Sciences, Inc. on Feb 12th 20'.
In addition to the pipeline products it has developed itself, Nurix recently inked two strategic collaborations with Sanofi and Gilead Sciences to develop novel protein degradation therapies in a range of therapeutic areas.
Jan 1, 2020 | pharmalive.comSarepta Therapeutics, Inc. sold assets to Gilead Sciences, Inc. in the amount of $125M on Feb 21st 17'.
Sarepta Therapeutics has sold its priority review voucher (PRV) to Gilead for $125 million.
Jan 1, 2017 | pharmacist.comAmazon Web Services partnered with Gilead Sciences, Inc. on Dec 2nd 21'.
Amazon Web Services this week announced a partnership in the cloud with Gilead Sciences Inc., a biopharmaceutical company.
Jan 1, 2021 | awsinsider.netGilead Sciences, Inc. decreases headcount by 114
Gilead Sciences Inc. will cut 114 jobs at the former New Jersey headquarters of acquisition of Immunomedics Inc. but has purchased property in Southern California to build more manufacturing space.
Jan 1, 2022 | bizjournals.comGilead Sciences, Inc. invests into The North Carolina AIDS Action Network in $250K
Raleigh – The North Carolina AIDS Action Network has been awarded a grant of $250,000 from Gilead Sciences to support the organization’s upcoming Ella/Her Project.
Jan 1, 2022 | ncaan.orgGilead Sciences, Inc. launched results from TROPiCS-02 study for drug Trodelvy on Feb 15th 22'.
Gilead Sciences, Inc. (NASDAQ:GILD) recently revealed new results from its TROPiCS-02 study for its drug Trodelvy, which outperformed chemotherapy at staving off disease progression or death in heavily pretreated patients with HR-positive, HER2-negative metastatic breast cancer.
Jan 1, 2022 | baystreet.caGilead Sciences, Inc. closes offices in New Jersey, United States
While Gilead is closing a manufacturing site in New Jersey and laying off 114, it also has acquired land in Oceanside, Calif., to expand its plant there.
Jan 1, 2022 | fiercepharma.comGilead Sciences, Inc. received financing of $24M in grants on Mar 28th 22'.
Funding Will Reach Under-Resourced Communities Most Impacted by the HIV Epidemic and COVID-19 Pandemic – Gilead Sciences, Inc., today announced $24 million in grants to help reduce health disparities, improve access to quality healthcare, advance medical education and support local communities most impacted by the HIV epidemic and COVID-19 pandemic.
Jan 1, 2022 | investingnews.comNASH Alliance partners with Gilead Sciences, Inc.
View the full release here: https://www.businesswire.com/news/home/20190412005104/en/ “NASH Alliance is very pleased about the potential to enter into this clinical collaboration with Gilead, which would combine Novo Nordisk’s semaglutide program in NASH with Gilead’s clinical programs to provide novel approaches for the treatment of NASH.
Jan 1, 2017 | gilead.comGilead Sciences, Inc. partners with Ebenezeramechurch
Balm in Gilead, a Virginia-based nonprofit, is partnering with Ebenezer AME Church in Lincolnville to establish a community garden that is part of its Food Security Project across South Carolina.
Jan 1, 2021 | postandcourier.comGilead Sciences, Inc. expanded offices to Dublin, County Dublin, Ireland on Apr 6th 22'.
Global biotech firm Gilead Sciences has opened a new Dublin city centre office that will employ 33 people.
Jan 1, 2022 | thinkbusiness.ieGilead Sciences, Inc. will expand facilities to Ireland on Dec 31st 22'.
Gilead Sciences' new pediatric center out of Ireland will conduct pediatric clinical trials for seven products across 18 countries.
Jan 1, 2022 | fiercebiotech.comGilead Sciences, Inc. has issues with claims that it violated the False Claims Act
Gilead Sciences Inc. must face claims that it violated the False Claims Act by establishing sham speaker programs to give meals and vacations to high-volume prescribers of drugs to treat hepatitis C, a Pennsylvania district court said.
Jan 1, 2022 | bloomberglaw.comGilead Sciences, Inc. invests into Precision Biosciences, Inc in $300M
So far, Precision has raised $300 million in financing from outside investors, including venBio, Franklin Templeton, Cowen Healthcare and Gilead, among others.
Jan 1, 2019 | heraldsun.comGilead Sciences, Inc. recognized as one of the top 10 pharmaceutical companies in the world
Established in 1987 and headquartered in California, Gilead Sciences is one of the top 10 pharmaceutical companies in the world.
Jan 1, 2019 | pharmiweb.comGoldfinch Bio, Inc. partnered with Gilead Sciences, Inc. on May 8th 19'.
Goldfinch Bio, headquartered in Cambridge, Massachusetts, was launched in 2016 by Third Rock Ventures and has an established strategic collaboration with Gilead Sciences, Inc.
Jan 1, 2019 | goldfinchbio.comGilead Sciences, Inc. expanded facilities to Amsterdam, Netherlands on Jul 27th 18'.
Gilead recently announced that it's building a CAR-T manufacturing plant at the Amsterdam airport in an effort to cut down on logistics and manufacturing turnaround time.
Jan 1, 2018 | fiercepharma.comGilead Sciences, Inc. is developing NK cell engager programs
The agreement also grants Gilead options, after the completion of certain preclinical activities, to license exclusive, worldwide rights to develop and commercialize additional NK cell engager programs using the Dragonfly Tri-specific NK Engager (TriNKET™) platform.
Jan 1, 2022 | pharmiweb.comGilead Sciences, Inc. is developing ultra-long-acting oral HIV therapies on Jul 1st 19'.
In July 2019, Lyndra Therapeutics, a biopharmaceutical company, announced a partnership with Gilead Sciences, Inc., a biotechnology company, to develop and commercialize ultra-long-acting oral HIV therapies.
Jan 1, 2022 | globenewswire.comGilead Sciences, Inc. launched findings from two studies on Apr 24th 22'.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced findings from two studies, which provide further insights on the use of Veklury ® (remdesivir) for the treatment of hospitalized and non-hospitalized patients with COVID-19.
Jan 1, 2022 | gilead.comGilead Sciences, Inc. partnered with Gritstone bio on Jul 19th 21'.
Gilead Sciences also announced a very interesting partnership during the first half of 2021, this time with Gritstone Oncology to create a vaccine-based immunotherapy as a cure for HIV.
Jan 1, 2021 | scienceboard.netGilead Sciences, Inc. increases headcount by 500
Gilead, the global biopharmaceutical company headquartered in Foster City, California, is looking to greatly expand its presence in New Jersey, where it intends to create an East Coast hub that eventually will employ 500 people, company officials told ROI-NJ.
Jan 1, 2022 | roi-nj.comGilead Sciences, Inc. invests into assets : 28-acre land site in Oceanside, California, United States
Gilead Sciences acquired a nearly 28-acre land site in Oceanside, California, for a planned expansion of its local biotech operations.
Jan 1, 2022 | pacificcoastcommercial.comGilead Sciences, Inc. hired Robin as Senior Vice President and Chief Financial Officer on Jan 1st 08'.
Robin joined Gilead Sciences, Inc. (NASDAQ: GILD) in 2008 as Senior Vice President and Chief Financial Officer, and expanded her role to include operational responsibilities as Executive Vice President from 2014 until her retirement in 2019.
Jan 1, 2022 | businesswire.comGilead Sciences, Inc. is developing RSV antivirals while KU Leuven
Under the agreement, Gilead Sciences receives exclusive global rights to develop the RSV antivirals while KU Leuven will be eligible to receive milestone payments and royalties on net sales of products developed under the agreement.
Jan 1, 2022 | sciencebusiness.netGilead Sciences, Inc. recognized as top spot in the U.S. and number three worldwide
In the latest annual breakdown of HIV giving from the Funders Concerned About AIDS (FCAA), Gilead Sciences took the top spot in the U.S. and number three worldwide.
Jan 1, 2022 | fiercepharma.comGilead Sciences, Inc. invested into Exavir Therapeutics in $4M on May 23rd 22'.
Exavir Therapeutics, a company dedicated to transforming the lives of people living with or at risk of acquiring HIV, today announced that the company has closed on a $4M seed financing led by AlleyCorp with participation from Gilead Sciences.
Jan 1, 2022 | biospace.comGilead Sciences, Inc. hired Greg Alton as interim CEO on Jan 1st 19'.
The company announced the appointment of Greg Alton, former interim CEO and general counsel of Gilead Sciences, as its lead independent board member.
Jan 1, 2022 | theepochtimes.comGilead Sciences, Inc. hired Stacey Ma as Chairman and Chief Executive Officer on Jun 2nd 22'.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Stacey Ma, PhD will join the company as Executive Vice President, Pharmaceutical Development and Manufacturing, and will become a member of the company’s senior leadership team, reporting to Chairman and Chief Executive Officer Daniel O’Day.
Jan 1, 2022 | businesswire.comGilead Sciences, Inc. received award Pulitzer Prize for Fiction on Jun 1st 14'.
Gilead (OBG June 2014) won the Pulitzer Prize for Fiction,, Home.
Jan 1, 2021 | fobl.org.auGilead Sciences, Inc. hired Dustin Haines as Senior Vice President, Intercontinental Region & Global Patient Solutions on Jun 6th 22'.
Gilead Sciences, Inc. today announced that Dustin Haines will be joining the company as Vice President, General Manager, Asia 5, effective 6 June 2022.
Jan 1, 2022 | prnasia.comGilead Sciences, Inc. decreases headcount by 100
At the same time, Gilead disclosed in a New Jersey Worker Adjustment and Retraining Notification notice that it was planning to lay off more than 100 workers at Immunomedics’ former headquarters in Morris Plains, New Jersey.
Jan 1, 2022 | fiercepharma.comGilead Sciences, Inc. invested into Aidsmemorial in $2.4M on Jun 12th 22'.
In the midst of this powerful backdrop, the National AIDS Memorial announced a $2.4 million grant from Gilead Sciences to launch the Quilt Southern Initiative to create new Quilt programming to address the disproportionate impact of HIV in the Southern U.S. Working together with the Southern AIDS Coalition and other community partners, the National AIDS Memorial will launch a Call My Name Southern Quilting program, organizing new panel-making workshops to ensure that southern communities and stories are reflected in the Quilt, to build on the Quilt’s legacy of activism, and to raise greater awareness of lives lost to HIV/AIDS, then and now.
Jan 1, 2022 | the360mag.comTaiyin Yang retired from Gilead Sciences, Inc. on Jun 9th 22'.
She will succeed Taiyin Yang, PhD, who is retiring from Gilead after nearly three decades.
Jan 1, 2022 | pharmaceuticalcommerce.comGilead Sciences, Inc. is developing NK cell engager programs
Gilead has an exclusive, worldwide option to develop and commercialize additional NK cell engager programs by using its Tri-specific NK Engager (TriNKET) platform after the completion of certain preclinical activities.
Jan 1, 2022 | dealforma.comGilead Sciences, Inc. recognized as top overall philanthropic funder of HIV/AIDS programs on Jun 28th 22'.
Today’s Transformative Grants announcement comes just weeks after Gilead was named the top overall philanthropic funder of HIV/AIDS programs, as revealed by the annual tracking report released by Funders Concerned About AIDS (FCAA).
Jan 1, 2022 | gileadcompass.comGilead Sciences, Inc. is developing antiviral drug used to treat COVID-19
The wife of GOP Sen. Rand Paul of Kentucky bought stock in Gilead Sciences, which went on to develop an antiviral drug used to treat COVID-19.
Jan 1, 2022 | venturecurrent.comBrett Pletcher retired from Gilead Sciences, Inc. as general counsel on Jan 13th 22'.
Ms. Telman will succeed Brett Pletcher, who is retiring from Gilead after 17 years with the company.
Jan 1, 2022 | gilead.comGilead Sciences, Inc. launches Truvada
In 2004, Gilead Sciences introduced Truvada to the U.S. market and, eight years later, the drug was approved by the Food and Drug Administration for HIV pre-exposure prophylaxis (PrEP).
Jan 1, 2022 | prweek.comGilead Sciences, Inc. acquired MiroBio for $405M on Jul 4th 22'.
For $405 million, Gilead will buy MiroBio, an Oxford spinout which just a month ago announced its £80 million Series B round.
Jan 1, 2022 | endpts.comGilead Sciences, Inc. launched updates to the NCCN Guidelines for Breast Cancer regarding sacituzumab govitecan-hziy (Trodelvy on Aug 3rd 22'.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced recent updates to the NCCN Guidelines ® for Breast Cancer regarding sacituzumab govitecan-hziy (Trodelvy ® ) in two types of metastatic breast cancer.
Jan 1, 2022 | gilead.comSpectrumhealth partners with Gilead Sciences, Inc.
As part of the NHS England HCV Elimination Programme, Spectrum has teamed up with Gilead Sciences for the ‘BBV Prison Project’.
Jan 1, 2022 | spectrumhealth.org.ukGilead Sciences, Inc. partnered with Satcher Health Leadership Institute on Aug 18th 22'.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced a new health equity collaboration with the Satcher Health Leadership Institute (SHLI) at Morehouse School of Medicine and the Center for Minority H ...more Kennedy Williams • 83 Views • August 18th, 2022
Jan 1, 2022 | hbcuconnect.comEverest Medicines Limited partners with Gilead Sciences, Inc.
Everest Medicines will also participate in the global Phase 3 study in Asia through its existing collaboration agreement with Gilead.
Jan 1, 2022 | yahoo.comGilead Sciences, Inc. acquired Immunomedics on Oct 1st 20'.
Gilead subsequently acquired Immunomedics in October 2020 and created an extensive global clinical development program, including investigating Trodelvy as a monotherapy.
Jan 1, 2022 | labiotech.euGilead Sciences, Inc. received financing of $5M in renewal funding on Oct 1st 19'.
The Wake Forest University School of Divinity received a $5 million grant from pharma giant Gilead Sciences to launch a faith-based center to address the HIV epidemic in the South, notably among vulnerable populations including African Americans, LGBTQ individuals and rural communities in Appalachia, according to an announcement from the school.
Jan 1, 2019 | poz.comGilead Sciences, Inc. had issues with CAR-T therapy Yescarta infringed on patents that were licensed to Juno on Jan 1st 17'.
Juno – which was acquired by Celgene and then Bristol Myers Squibb — sued Gilead’s Kite unit back in 2017, alleging that the company’s CAR-T therapy Yescarta infringed on patents that were licensed to Juno by Memorial Sloan Kettering Cancer Center.
Aug 26, 2022 | endpts.comGilead Sciences, Inc. invests into Kyverna Therapeutics, Inc.
Meanwhile, Gilead Sciences ( GILD ) invested in an early fundraising round for Kyverna Therapeutics.
Aug 29, 2022 | thestreet.comGilead Sciences, Inc. invests into Howard Brown in $1M
Howard Brown Health has been awarded a three-year, $1 million grant from Gilead Sciences, Inc. to fund a campaign aimed at reducing new HIV infections in Chicago.
Aug 28, 2022 | howardbrown.orgGilead Sciences, Inc. launched data from a post hoc subgroup analysis from the Phase 3 TROPiCS-02 study evaluating Trodelvy versus comparator chemotherapies on Sep 4th 22'.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from a post hoc subgroup analysis from the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy) versus comparator chemotherapies (physicians’ choice of chemotherapy, TPC) in patients with HR+/HER2- metastatic breast cancer who progressed on endocrine-based therapies and at least two chemotherapies.
Jun 6, 2022 | otcdynamics.comGilead Sciences, Inc. launches Press Play
To help normalize HIV testing, Gilead launched Press Play, a resource to encourage routine testing as a regular part of self-care and help deter negative emotions or stigma associated with HIV screenings.
Sep 8, 2022 | loganbanner.comGilead Sciences, Inc. invests into Claflin in $525K
Claflin University was awarded $525,000 from Gilead Sciences, Inc. to support initiatives and programs conducted by the University’s Center for Social Justice.
Sep 15, 2022 | claflin.eduGilead Sciences, Inc. partners with AIDS United
This is not the first time Gilead has partnered with AIDS United to provide hurricane relief.
Sep 26, 2022 | vacationer.travelGilead Sciences, Inc. hired Jesse on Oct 13th 19'.
Jesse joined Gilead three years ago, and during this time he has prioritized working on health equity, inclusion and diversity issues.
Oct 13, 2022 | gilead.comGilead Sciences, Inc. is developing MGD024
Gilead Sciences, Inc. and MacroGenics, Inc. entered an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics’ DART platform, and two additional bispecific research programs.
Oct 17, 2022 | contractpharma.comGilead Sciences, Inc. is developing bispecific antibody to treat hematological cancers
Gilead Sciences and MacroGenics entered into a licensing and collaboration pact worth up to $1.7 billion to develop a bispecific antibody to treat hematological cancers.
Oct 17, 2022 | biospace.comGilead Sciences, Inc. partners with MacroGenics, Inc.
Gilead Sciences, Inc. and MacroGenics, Inc. entered an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics’ DART platform, and two additional bispecific research programs.
Oct 16, 2022 | contractpharma.comGilead Sciences, Inc. receives award Corporate Leadership Award
SAGE will also honor Gilead Sciences with the Corporate Leadership Award.
Oct 9, 2022 | outtakeonline.comGilead Sciences, Inc. partnered with Refugebiotech on Oct 20th 22'.
Kite, a Gilead Company, has signed a global license agreement with Refuge Biotechnologies, a synthetic biology company for cancer immunotherapy, for exclusive rights to use latter’s gene expression platform to develop potential treatments for blood cancers.
Oct 20, 2022 | pharmaceutical-business-review.comGilead Sciences, Inc. will develop potential blood cancer therapies on Oct 27th 22'.
Gilead Sciences' Kite Pharma entered into a global licensing deal with Refuge Biotechnologies Thursday to leverage the latter's propriety gene expression platform and develop potential blood cancer therapies.
Oct 20, 2022 | biospace.comGilead Sciences, Inc. is developing NK cell engager programs
The agreement also grants Gilead options, after the completion of certain preclinical activities, to license exclusive, worldwide rights to develop and commercialize additional NK cell engager programs using the Dragonfly Tri-specific NK Engager (TriNKET) platform.
Oct 11, 2022 | pharmalive.comGilead Sciences, Inc. invests into Community Education Group in $50K
The Community Education Group received $50,000 in grants each from Gilead Sciences and ViiV Healthcare to develop and distribute materials, offer grants and hold meetings aimed at reducing cultural stigmas and barriers related to the virus, the group said in a statement.
Oct 31, 2022 | wset.comGilead Sciences, Inc. partnered with ISPE Foundation on Oct 28th 22'.
The ISPE Foundation announced Gilead Sciences, Inc. (Gilead) is partnering with the Foundation to establish a new Technology Without Borders initiative.
Oct 28, 2022 | ispe.orgGilead Sciences, Inc. launched in-vitro activity of remdesivir against 10 SARS-CoV-2 variants on Jan 1st 20'.
Gilead Sciences has released data showing the in-vitro activity of remdesivir (Veklury) against 10 SARS-CoV-2 variants.
Feb 18, 2022 | pharmacytimes.comGilead Sciences, Inc. partners with Xula
Gilead has previously partnered with Xavier in solidarity with the institutions’ commitments to advancing global health equity and improving health outcomes for all.
Sep 12, 2022 | xula.eduOutpost379 partners with Gilead Sciences, Inc.
Outpost379 worked with Gilead early in the pandemic to be in market with “Bet on Them,” showing support for infectious disease physicians and nurses in the fight against COVID-19.
Nov 15, 2022 | strategyonline.caGilead Sciences, Inc. recognized as Top Socially Responsible Dividend Stock
Gilead Sciences Inc (Symbol: GILD) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 3.3% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of social and environmental criteria.
Dec 6, 2022 | nasdaq.comGilead Sciences, Inc. had issues with separate patent-infringement lawsuit on Jan 1st 19'.
The opinion could strengthen Gilead's defense in a separate patent-infringement lawsuit in Delaware where the U.S. government is seeking more than $1 billion in damages from the pharmaceutical firm over the HIV drug regimen known as PrEP.
Dec 1, 2022 | pharmacytoday.orgImmunoGen, Inc. partnered with Gilead Sciences, Inc. on Dec 9th 22'.
ImmunoGen entered into a clinical collaboration deal with Gilead Sciences Friday to evaluate the safety and efficacy of two drugs that, when used in concert, have the potential to treat AML, a blood disorder biopharma has found challenging to target.
Dec 9, 2022 | biospace.comGilead Sciences, Inc. partnered with Dragonflytx on May 2nd 22'.
A collaboration between Gilead Sciences and Dragonfly Therapeutics was announced today, with an end goal of bringing Dragonfly's DF7001 natural killer (NK) engager program designed for patients with cancer or inflammatory diseases to fruition.
May 2, 2022 | biospace.comGilead Sciences, Inc. partners with Arcellx, Inc.
In partnering with clinical-stage Arcellx, Gilead Sciences gains the opportunity to develop a cell therapy for multiple myeloma that could offer advantages over currently available therapies for the blood cancer.
Dec 9, 2022 | medcitynews.comGilead Sciences, Inc. recognized as one of the most sustainable pharmaceutical companies according to the Dow Jones Sustainability World Index (DJSI World) on Dec 12th 22'.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company has once again been recognized as one of the most sustainable pharmaceutical companies according to the Dow Jones Sustainability World Index (DJSI World).
Dec 12, 2022 | gilead.comGilead Sciences, Inc. launches Sovaldi
When Gilead launched Sovaldi, the first-ever cure for hepatitis C, in late 2013, it charged $84,000 for a course of treatment.
Dec 15, 2022 | statnews.comAndreose leaves Gilead Sciences, Inc. as SVP Intercontinental Region
Andreose comes from Gilead Sciences, where he served as SVP Intercontinental Region.
Dec 15, 2022 | pharmaphorum.comGilead Sciences, Inc. acquired Tmunity Therapeutics, Inc. on Dec 21st 22'.
Looking to further boost its growing cell therapy business, Gilead Sciences on Wednesday said it plans to acquire Tmunity Therapeutics, a private biotechnology company trying to develop newer, better CAR-T treatments.
Dec 20, 2022 | biopharmadive.comGilead Sciences, Inc. partnered with Tmunity Therapeutics, Inc. on Jun 1st 22'.
Gilead Sciences subsidiary Kite Pharma has entered into a purchase deal with Tmunity Therapeutics — the company founded by CAR-T cell pioneer Carl June — gaining access to Tmunity’s “armored” CAR-T cell platform.
Dec 21, 2022 | fdanews.comJounce Therapeutics, Inc. sold assets to Gilead Sciences, Inc. in the amount of $67M on Dec 20th 22'.
(Reuters) - Gilead Sciences will buy all the remaining rights for an experimental cancer therapy, GS-1811, from Jounce Therapeutics for $67 million, the drugmaker said on Tuesday.
Dec 13, 2022 | yahoo.com